Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer’s Disease: Need for Prognostic Biomarkers?-Reference-Cited by-同舟云学术

Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer’s Disease: Need for Prognostic Biomarkers?

Published:2016-05-10 Issue:2 Volume:52 Page:417-420
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Piazza Fabrizio¹²³,Winblad Bengt⁴

Affiliation:

1. The inflammatory cerebral amyloid angiopathy and Alzheimer’s disease βiomarkers (iCAβ) International Network, Monza, Italy

2. The iCAβ-ITALY Study Group of the Italian Society for the study of Dementia (SINdem), Italy

3. School of Medicine and Surgery, Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Monza, Italy

4. Karolinska Institutet, Department of NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference16 articles.

1. MR imaging features of amyloid-related imaging abnormalities;Barakos;AJNR Am J Neuroradiol,2013

3. Anti-Abeta autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy;DiFrancesco;Frontiers Neurol,2015

4. OC4: Efficacy and safety of gantenerumab from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD;Lasser;J Prev Alzheimers Dis,2015

5. OC5: CSF and amyloid PET biomarker data from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD;Nikolcheva;J Prev Alzheimers Dis,2015

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics;Frontiers in Aging Neuroscience;2024-08-09

2. Differences in the cerebral amyloid angiopathy proteome in Alzheimer’s disease and mild cognitive impairment;Acta Neuropathologica;2024-07-22

3. Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond;Journal of Clinical Medicine;2024-05-25

4. Immunotherapy in Alzheimer’s disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline;Journal of Pharmacy and Pharmacology;2024-05-20

5. Clearance of interstitial fluid (ISF) and CSF (CLIC) group‐part of Vascular Professional Interest Area (PIA), updates in 2022‐2023. Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy;Alzheimer's & Dementia;2023-10-28